Monoclonal antibodies targeting AREG directly neutralize its activity, blocking EGFR signaling and inhibiting tumor growth, as demonstrated by the AR37 antibody, which prolongs survival in preclinical cancer models and shows potential in treating fibrotic diseases due to its ability to reduce fibroblast activation [187]. This evidence concerns the gene EGFR and neoplasm.